Managing Drug-Drug Interaction between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Therapeutic Drug Monitoring Année : 2017

Managing Drug-Drug Interaction between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil

Résumé

No drug-drug interaction study has been conducted to date for the combination of ombitasvir, paritaprevir/ritonavir, dasabuvir (3D), and mycophenolic acid (MPA). We here report the case of a hepatitis C virus-infected patient treated with 3D and MPA for vasculitis. In light of the threat of drug-drug interaction, the concentration of MPA was measured before, during, and 15 days after the end of the 3D treatment. Similar values were found at all 3 time points, thus indicating that there is probably no need to adapt MPA dosage to 3D. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Fichier non déposé

Dates et versions

hal-01614699 , version 1 (11-10-2017)

Identifiants

Citer

F. Lemaitre, Z. Ben Ali, C. Tron, C. Jezequel, C. Boglione-Kerrien, et al.. Managing Drug-Drug Interaction between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil. Therapeutic Drug Monitoring, 2017, 39 (4), pp.305-307. ⟨10.1097/FTD.0000000000000397⟩. ⟨hal-01614699⟩
31 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More